Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8480640 | 0.83 | OPRM1 (0.52) | OPRM1CHRM2CHRM3SIGMAR1KMT2A | |
| SCHEMBL5725684 | 0.82 | OPRM1 (0.51) | OPRM1CHRM4CHRM2CHRM3ACHE | |
| SCHEMBL6657986 | 0.82 | LTA4H (0.52) | OPRM1CHRM2CHRM3ALDH1A1ACHE | |
| SCHEMBL28741984 | 0.81 | OPRM1 (0.53) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL1205295 | 0.81 | ACHE (0.45) | OPRM1CHRM4CHRM2CHRM3KDM4E | |
| SCHEMBL8189152 | 0.79 | CCR5 (0.58) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL803672 | 0.79 | SIGMAR1 (0.59) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL34474746 | 0.78 | CCR5 (0.53) | OPRM1CHRM4CHRM2CHRM3KDM4E | |
| SCHEMBL7499304 | 0.78 | CCR5 (0.53) | OPRM1CHRM4CHRM2CHRM3KDM4E | |
| SCHEMBL16054269 | 0.78 | OPRM1 (0.59) | OPRM1CHRM2CHRM3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579341-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | OPRM1 44/4885CHRM4 238/4885CHRM2 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.